Publications

Professor Bradley is the William Ziegler Professor of Business Administration Emeritus at the Harvard Business School. In addition to teaching Management and Strategy in the Owner President Management Program and leading an... View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

20 Nov 2007
First Look

First Look: November 20, 2007

a period of financial repression. Nationalization led to lower interest rates and lower quality intermediation and may have slowed employment gains in trade and services. Development lending goals were met, but these had no real impact. Finally, View Details

Keywords: Martha Lagace

February 2001 (Revised July 2006)
Case

Discovering the Future: R&D Strategy at Merck

By: Gary P. Pisano

Given explosive growth in technologies for drug discovery, how does Merck remain competitive in an industry that is fragmented and continues to consolidate? View Details

Keywords: Competitive Strategy; Research and Development; Pharmaceutical Industry

September 2023 (Revised December 2023)
Case

TetraScience: Noise and Signal

By: Thomas R. Eisenmann and Tom Quinn

In 2019, TetraScience CEO “Spin” Wang needed advice. Five years earlier, he had cofounded a startup that saw early success with a hardware product designed to help laboratory scientists in the biotechnology and pharmaceutical spaces more easily collect data from... View Details

Keywords: Entrepreneurship; Business Growth and Maturation; Business Organization; Restructuring; Forecasting and Prediction; Digital Platforms; Analytics and Data Science; AI and Machine Learning; Organizational Structure; Network Effects; Competitive Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States; Boston

Elon Kohlberg is the Royal Little Professor of Business Administration at the Harvard Business School. His research is mainly in Game Theory, in particular the study of non-cooperative equilibrium.

Professor Kohlberg has taught many courses in the MBA,... View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

06 May 2008
First Look

First Look: May 6, 2008

company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing... View Details

Keywords: Martha Lagace

Gary P. Pisano

Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

03 Apr 2007
First Look

First Look: April 3, 2007

different development strategies. The states had to decide whether to focus their investment efforts on physical capital or improving social indicators. Both states faced constraints in the form of budget deficits, competition from other... View Details

Keywords: Martha Lagace

12 Feb 2008
First Look

First Look: February 12, 2007

Working PapersColonial Land Tenure, Electoral Competition and Public Goods in India Authors:Abhijit Banerjee and Lakshmi Iyer No abstract is available at this time. Download the paper: http://www.hbs.edu/research/pdf/08-062.pdf... View Details

Keywords: Martha Lagace

02 Aug 2011
First Look

First Look: August 2

pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks revealed its vulnerability to political risk. Following the advent of the Nazi regime in 1933, the largely Jewish owned and managed... View Details

Keywords: Sean Silverthorne

16 Jan 2018
First Look

First Look at New Research and Ideas, January 16, 2018

explores whether the strategy will save the Chinese economy or generate social and political problems that imperil the country's growth and stability. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=53716 Lone Wolves in View Details

Keywords: Sean Silverthorne

Nitin Nohria

Nitin Nohria served as the tenth dean of Harvard Business School from 2010-2020. He previously served as co-chair of the Leadership Initiative, Senior Associate Dean of Faculty Development, and Head of the Organizational Behavior unit.

As Dean, building on... View Details

June 1999 (Revised June 2000)
Case

Eckerd Corporation

By: Michael E. Porter and John E. Kelleher

Describes the history and current situation in the retail pharmacy industry, including competition from new merchants and Internet drugstores. Eckerd, one of the top four drug chains, must decide how to position itself for the future. View Details

Keywords: Competition; Alignment; Supply and Industry; Pharmaceutical Industry; Pharmaceutical Industry

October 2019
Case

Impax Laboratories: Executing Accretive Acquisitions (A)

By: Benjamin C. Esty and Daniel Fisher

Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details

Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States

October 2019
Supplement

Impax Laboratories: Executing Accretive Transactions (A)

By: Benjamin C. Esty and Daniel Fisher

Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details

Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Financial Strategy; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States